Advertisement

Blasenkarzinom

  • Andreas Böhle
  • Sven Brandau
  • Christoph Durek
  • Peter Ardelt
  • Ingo Kausch
Part of the Molekulare Medizin book series (MOLMED)

Zusammenfassung

Berichte über Erkrankungen der Harnblase finden sich bereits in der Antike mit Darstellungen von Hämaturie in Malereien der alten ägypter. Es wird heute davon ausgegangen, dass diese die weit verbreitete Hämaturie bei der urogenitalen Bilharziose beschreiben. Weiterhin beschäftigten sich ganze Generationen von Heilern mit dem Phänomen des schwarzen Urins im Mittelalter, dessen mögliche Ursache die altblutige Makrohämaturie beim Blasenkarzinom sein kann. Weitere Berichte über Geschwüwre der Harnblase sind aus folgenden Gründen sehr selten:
  1. 1.

    Es war lediglich eine blinde Untersuchung der Harnrohre und Harnblase allenfalls durch Katheter und Sonden moglich.

     
  2. 2.

    Die Urochirurgie orientierte sich tiber viele Jahrhunderte an der Steinschneiderei.

     

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adshead JM, Kessling AM, Ogden CW (1998) Genetic initiation, progression and prognostic markers in transitional cell carcinoma of the bladder: a summary of the structural and transcriptional changes, and the role of developmental genes. Br J Urol 82:503–512PubMedGoogle Scholar
  2. Alizadeh AA, Eisen MB, Davis RE et al. (2000) Distinct types of diffuse large B-celllymphoma identified by gene expression profiling. Nature 403:503–511PubMedGoogle Scholar
  3. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921PubMedGoogle Scholar
  4. Atkin NB, Fox MF (1990) 5q deletion: the sole chromosome change in a carcinoma of the bladder. Cancer Genet Cytogenet 46:29Google Scholar
  5. Augustine A, Hebert JR, Kabat GC (1988) Bladder cancer in relation to cigarette smoking. Cancer Res 48:4405PubMedGoogle Scholar
  6. Barbacid MA (1987) ras genes. Annu Rev Biochem 56:779PubMedGoogle Scholar
  7. Bardenheuer B (1997) Die Erstbeschreibung der totalen Zystektomie mit historischer Betrachtung ihrer weiteren Entwicklung als wesentliche urologische Operation. Aktuelle Urol 28:21–24Google Scholar
  8. Bass C, Cabrera G, Eigavish A et al. (1995) Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo. Cancer Gene Ther 2:97–104PubMedGoogle Scholar
  9. Bianco FJ Jr, Gervasi DC, Tiguert R et al. (1998) Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clin Cancer Res 4:3011–3016PubMedGoogle Scholar
  10. Birchmeier W (1995) E-cadherin as a tumor (invasion) suppressor gene. Bioessays 17:97–99PubMedGoogle Scholar
  11. Bochner BH, Cote RJ, Weidner N et al. (1995) Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 87:1603–1612PubMedGoogle Scholar
  12. Bonner RB, Hemstreet GP, Fradet Y, Rao JY, Min KW, Hurst RE (1993) Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells. Cancer 72:2461–2469PubMedGoogle Scholar
  13. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49:4682–4689PubMedGoogle Scholar
  14. Brandau S, Riemensberger J, Ulmer AJ, Flad H-D, Jocham D, Böhle A (1999) Analysis of an in vitro system to characterize the immunological mechanism of the immunotherapy of bladder cancer with Bacillus Calmette Guérin (BCG). Eur J Cancer [Suppl 5] 35:18Google Scholar
  15. Bravo R, Macdonald-Bravo H (1985) Changes in the nuclear distribution of cyclin (PCNA) but not its synthesis depend on DNA replication. EMBO J 4:655–661PubMedCentralPubMedGoogle Scholar
  16. Bretton P, Cordon-Cardo C, Wartinger D, Kimmel M, Fair WR, Melamed MR, Fradet Y (1990) Expression of the T-138 antigen and survival of patients with bladder cancer. Proc Am Assoc Cancer Res 31:186, abstract 1105Google Scholar
  17. Campbell SC, Tanabe K, Alexander JP, Edinger M, Tubbs RR, Klein EA (1994) Intercellular adhesion molecule-I expression by bladder cancer cells: functional effects. J Urol 151:1385–1390PubMedGoogle Scholar
  18. Chaudhary R, Bromley M, Clarke NW et al. (1999) Prognostic relevance of micro-vessel density in cancer of the urinary bladder. Anticancer Res 19:3479–3484PubMedGoogle Scholar
  19. Chen L, Chen D, Block E, O’Donnell M, Kufe DW, Clinton SK (1997) Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol 159:351–359PubMedGoogle Scholar
  20. Chi S.G., Chang S.G., Lee SJ, Lee CH, Kim JI, Park JH (1999) Elevated and biallelic expression of p73 is associated with progression of human bladder cancer. Cancer Res 59: 2791–2793PubMedGoogle Scholar
  21. Chopin DK, Caruelle JP, Colombel M et al. (1993) Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol 150:1126–1130PubMedGoogle Scholar
  22. Chow NH, Cheng CJ, Chi YC, Liu HS, Tzai TS, Lin JS (1998) Potential value of urinary intercellular adhesion molecule-1 determination in patients with bladder cancer. Urology 52:1015–1019PubMedGoogle Scholar
  23. Clavel J, Cordier S, Boccon-Gibod L, Hemon D (1989) Tobacco and bladder cancer in males: increased risk for inhalers and smokers of black tobacco. Int J Cancer44:605–610PubMedGoogle Scholar
  24. Cohen MB, Waldman FM, Carroll PR, Kerschmann R, Chew K, Mayall BH (1993) Comparison of 5 histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder. Hum Pathol24:772–778PubMedGoogle Scholar
  25. Cohen MB, Griebling TL, Ahaghotu CA, Rokhlin OW, Ross JS (1997) Cellular adhesion molecules in urologie malignancies.Am J Clin Pathol 107:56–63PubMedGoogle Scholar
  26. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E (1993) Regression of bladder tumors in miee treated with interleukin 2 gene-modified tumor cells. Exp Med 177:1127–1134Google Scholar
  27. Cordon-Cardo C, Reuter VE, Lloyd KO et al. (1988) Blood group-related antigens in human urothelium: enhanced expression of precursors, LeX and LeY determinants in urothelial carcinoma. Cancer Res 48:4113–4120PubMedGoogle Scholar
  28. Cordon-Cardo C, Wartinger D, Petrylak D et al. (1992) Altered expression of the retinoblastoma gene product:prognostic indicator in bladder cancer. J Natl Cancer Inst 84:1251–1256PubMedGoogle Scholar
  29. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner D.G (1997) p53 and treatment ofbladder cancer. Nature 385:123–125PubMedGoogle Scholar
  30. Crew JP, O’Brian T, Bieknell R, Fuggle S, Cranston D, Harris AL (1999) Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 161:799–804PubMedGoogle Scholar
  31. Crooke ST, Grillone LR, Tendolkar A, Garret A (1994) A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts. Clin Pharmacol Ther 56:641–646PubMedGoogle Scholar
  32. Dalbagni G, Reuter VE, Sheinfeld J, Fradet Y, Fair WR, Cordon-Cardo C (1992) Cell surface differentiation antigens of normal urothelium and bladder tumors. Sem Surg Oncol 8:293–299Google Scholar
  33. Dean N, McKay R, Miraglia L et al. (1996) Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kin ase C-α expression. Cancer Res 56:3499–3507PubMedGoogle Scholar
  34. D’Haliewin MA, Baert L (1996) Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urol 155:475–476Google Scholar
  35. Eder IE, Stenzl A, Hobisch A, Cronauer MV, Bartsch G, Klocker H (1996) Transforming growth factors beta-1 and beta-2 in serum and urine from patients with bladder cancer. J Urol 156:953–957PubMedGoogle Scholar
  36. Edgren M, Lennernas B, Larsson A, Nilsson S (1999) Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas. AntiCanc Res 19:869–873Google Scholar
  37. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL (1997) Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors.The Multi Center Study Group. Urology 50:882–887PubMedGoogle Scholar
  38. Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137–171PubMedGoogle Scholar
  39. Esrig D, Spruck CH, Nichols PW et al. (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Am J Pathol 143:1389–1397PubMedCentralPubMedGoogle Scholar
  40. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331:1259–1264PubMedGoogle Scholar
  41. Feng M, Cabrera G, Deshane J, Scanlon KJ, Curiel DT (1995) Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 55:2024–2028PubMedGoogle Scholar
  42. Feramisco JR, Gross M, Kamata T, Rosenberg M, Sweet RW (1984) Microinjection of the oncogene form of the human H-ras (T-24) protein results in rapid proliferation of quiescent cells. Cell 38:109–117PubMedGoogle Scholar
  43. Fitzpatriek JM, West AB, Butler MR, Lane V, O’Flynn JD (1986) Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol 135:920–922Google Scholar
  44. Folkman J, Klagsbrun M (1987) Vascular physiology. A family of angiogenic peptides. Nature 329:671–672PubMedGoogle Scholar
  45. Fontana D, Bellina M, Scoffone C et al (1996) Evaluation of c-ras on co gene product (p21) in superficial bladder cancer.Eur Urol 29:470–476PubMedGoogle Scholar
  46. Fradet Y (1998) phenotypic characterization of bladder cancer.Eur Urol [Suppl 4] 33:5–6PubMedGoogle Scholar
  47. Fradet Y, Cordon-Cardo C (1993) Critical appraisal of tumor markers in bladder cancer. Semin Urol 11:145–153PubMedGoogle Scholar
  48. Fradet Y, Tardif M, Bourget L, Robert J (1990) Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies.Laval University Urology Group. Cancer Res50:432–437PubMedGoogle Scholar
  49. Freeman SM, Abboud CN, Whartenby KA et al. (1993) The “bystander effect”: tumor regression when a fraction of the tumor mass is genetieally modified. Cancer Res53:5274–5283PubMedGoogle Scholar
  50. Freeman A, Morris LS, Mills AD et al. (1999) Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 5:2121–2132PubMedGoogle Scholar
  51. Freije JM, MacDonald NJ, Steeg PS (1998) Nm 23 and tumour metastasis: basic and translational advances. Biochem Soc Symp 63:261–271PubMedGoogle Scholar
  52. Fujimoto K, Yamada Y, Okajima E et al. (1992) Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 52:1393–1398PubMedGoogle Scholar
  53. Fujisawa M, Miyazaki J, Takechi Y, Arakawa S, Kamidono S (1996) The significance of E-cadherin in transitional-cell carcinoma of the human urinary bladder. World J Urol [Suppll] 14:12–15Google Scholar
  54. Garrido F, Ruiz-Cabello F (1991) MHC expression on human tumors-its relevance for local tumor growth and metastasis.Semin Cancer Biol 2:3–10PubMedGoogle Scholar
  55. Gazzaniga P, Gradilone A, Vercillo R, Gandini O, Silvestri I (1996) Becl-2/bax mRNA expression ratio as prognostic factor in low grade urinary bladder cancer. Int J Cancer69:100–104PubMedGoogle Scholar
  56. Gazzaniga P, Gandini O, Gradilone A et al. (1999) Detection of basic fibroblast growth factor mRNA in urinary bladder cancer: correlation with local relapses. Int J Oncol 14:1123–1127PubMedGoogle Scholar
  57. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuelear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710–1715PubMedGoogle Scholar
  58. Getzenberg RH, Konety BR, Oeler TA et al. (1996) Bladder cancer-associated nuelear matrix proteins. Cancer Res56:1690–1694PubMedGoogle Scholar
  59. Gilbert HA, Logan JL, Kagan AR et al. (1978) The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histological grading. J Urol 119:488–492PubMedGoogle Scholar
  60. Gohji K, Fujimoto N, Ohkawa J, Fujii A, Nakajima M (1998) Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer 77:650–655PubMedCentralPubMedGoogle Scholar
  61. Golijanin D, Sherman Y, Shapiro A, Pode D (1995) Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine. Urology 46:173–177PubMedGoogle Scholar
  62. Gray GD, Hernandez OM, Hebel D, Root M, Pow-Sang JM, Wickstrom E (1993) Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. Cancer Res 53:577–580PubMedGoogle Scholar
  63. Griffiths TR, Brotherick I, Bishop RI et al. (1996) Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer 74:579–584PubMedCentralPubMedGoogle Scholar
  64. Grim J, D’ Amico A, Frizelle S, Zhou J, Kratzke RA, Curiel DT (1997) Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paelitaxel. Clin Cancer Res 3:2415–2423PubMedGoogle Scholar
  65. Gros P, Croop J, Housman D (1986) Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport pro teins.Cell 47:371–380PubMedGoogle Scholar
  66. Grossfeld GD, Ginsberg DA, Stein JP et al. (1997) Thrombospondin-I expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression.J Natl Cancer Inst 89:219–227PubMedGoogle Scholar
  67. Grossman HB, Liebert M, Antelo M et al. (1998) p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4:829–834PubMedGoogle Scholar
  68. Grossman HB, Lee C, Bromberg J, Liebert M (2000) Expression of the alpha6 beta4 integrin provides prognostic information in bladder cancer. Oncol Rep 7:13–16PubMedGoogle Scholar
  69. Gueguen M, Patard JJ, Gaugier B et al. (1998) An antigen recognized by autologous CTLs on a human bladder carcinoma. J Immunol 160:6188–6194PubMedGoogle Scholar
  70. Habuchi T, Kinoshita H, Yamada H et al. (1994) Oncogene amplification in urothelial cancers with p53 gene mutation or MDM 2 amplification. J Natl Cancer Inst 86:1331–1335PubMedGoogle Scholar
  71. Hall MC, Li Y, Pong RC, Ely B, Sagalowsky A.I., Hsieh JT (2000) The growth inhibitory effect of p21 adenovirus on human bladder cancer cells. J Urol 163:1033–1038PubMedGoogle Scholar
  72. Harimoto K, Sugimura K, Lee CR, Kuratsukuri K, Kishimoto T (1998) In vivo gene transfer methods in the bladder without viral vectors. Br J Urol 81:870–874PubMedGoogle Scholar
  73. Hasui Y, Marutsuka K, Asada Y, Osada Y (1996) Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. Urology 47:34–37PubMedGoogle Scholar
  74. Heney NM, Ahmed S, Flanagan MJ et al. (1983) Superficial bladder cancer: progression and recurrence. J Urol 130:1083–1086PubMedGoogle Scholar
  75. Hogrefe RI (1999) An antisense oligonueleotide primer.Antisense Nucleic Acid Drug Dev 9:351–357PubMedGoogle Scholar
  76. Hölzel D, Altwein JE (1991) Tumoren des Urogenitaltraktes: Klinisch-epidemiologische Fakten. Urologe A 30:134–138PubMedGoogle Scholar
  77. Horiguchi Y, Larchian WA, Kaplinsky R, Fair WR, Heston WD (2000) Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther 7:844–851PubMedGoogle Scholar
  78. Huang YW, Baluna R., Viretta ES (1997) Adhesion molecules as targets for cancer therapy. Histol Histopathol 12:467–477PubMedGoogle Scholar
  79. Irie A, Anderegg B, Kashani-Sabet M et al. (1999) Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer. Antisense Nucleic Acid Drug Dev 9:341–349PubMedGoogle Scholar
  80. Izadifar V, Boer WI de, Muscatelli-Groux B, Maille P, Kwast TH van der, Chopin D (1999) Expression of transforming growth factor beta 1 and its receptors in normal human urothelium and human transitional cell carcinomas. Hum Pathol 30:372–377PubMedGoogle Scholar
  81. Jewett HJ (1977) The historical development of the staging of bladder tumors: personal reminiscences. Urol Surv 27:37–40PubMedGoogle Scholar
  82. Johnston B, Morales A, Emerson L, Lundie M (1997) Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 158:2098–2101PubMedGoogle Scholar
  83. Kamb A, Gruis NA, Weaver-Feldhaus J et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440PubMedGoogle Scholar
  84. Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S (1998) Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 82:1359–1366PubMedGoogle Scholar
  85. Kinoshita H, Ogawa O, Kakehi Y et al. (1997) Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst 89:724–730PubMedGoogle Scholar
  86. Kmiec EB (1996) Genomic targeting and genetic conversion in cancer therapy. Semin Oncol 23:188–193PubMedGoogle Scholar
  87. Knowles MA (1995) Molecular genetics of bladder cancer. Br J Urol 75:57–66PubMedGoogle Scholar
  88. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG (1994) Allelotype of human bladder cancer.Cancer Res 54:531–538PubMedGoogle Scholar
  89. Koc ON, Allay JA, Lee K, Davis BM, Reese JS, Gerson SL (1996) Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance. Semin Oncol 23:46–65PubMedGoogle Scholar
  90. Konchuba AM, Schellhammer PF, Alexander JP, Wright Jr GL (1989) Flow cytometric study comparing paired bladder washing and voided urine for bladder cancer detection.Urology 33:89–96PubMedGoogle Scholar
  91. Koss LG (1995) Diagnostic cytology of the urinary tract with histopathologic and clinical correlations. Lippencott-Raven, PhiladelphiaGoogle Scholar
  92. Kotake T, Saiki S, Kinouchi T, Shiku H, Nakayama E (1990) Detection of c-myc gene product in urinary bladder cancer. Jpn J Cancer Res 81:1198–1201PubMedGoogle Scholar
  93. Kroft SH, Oyasu R (1994) Biology of disease: urinary bladder cancer: mechanisms of development and progression.Lab Invest 71:158–174PubMedGoogle Scholar
  94. Kyo S, Kunimi K, Uchibayashi T, Namiki M, Inoue M (1997) Telomerase activity in human urothelial tumors. Am J Clin Pathol 107:555–560PubMedGoogle Scholar
  95. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC (1998) Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 52:398–402PubMedGoogle Scholar
  96. Lang NP, Kadlubar FF (1991) Aromatic and heterocyclic amine metabolism and phenotyping in humans. Prog Clin Biol Res 372:33–47PubMedGoogle Scholar
  97. Lee SS, Eisenlohr LC, McCue PA, Mastrangelo MJ, Lattime EC (1994) Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res 54:3325–3328PubMedGoogle Scholar
  98. Lee SH, Lee JY, Park WS, Kim SY, Jang JJ, Yoo NJ (1999a) Transitional cell carcinoma expresses high levels of Fas ligand in vivo. Br J Urol Int 83:698–702Google Scholar
  99. Lee SH, Shin MS, Park WS et al. (1999b) Alterations of FAS (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res 59:3068–3072PubMedGoogle Scholar
  100. Levesque P, Ramchurren N, Saini K, Joyce A, Libertino J, Summerhayes IC (1993) Screening of human bladder tumors and urine sediments for the presence of H-ras mutations. Int J Cancer 55:785–790PubMedGoogle Scholar
  101. Leyh H, Hall R, Mazemann E (1998) Wertigkeit von BTATest und Urinzytologic bei der Diagnostik und Nachsorge des Harnblasenkarzinoms. Aktuelle Urol 29:57–61Google Scholar
  102. Li Y, Pong RC, Bergelson JM et al. (1999) Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 59:325–330PubMedGoogle Scholar
  103. Lianes P, Orlow I, Zhang ZF et al. (1994) Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 86:1325–1330PubMedGoogle Scholar
  104. Liebert M, Washington R, Stein J, Wedemeyer G, Grossman HB (1994a) Expression of the VLA b1 integrin family in bladder cancer. Am J PathoI 144:1016–1022Google Scholar
  105. Liebert M, Washington R, Wedemeyer G, Carey T.E., Grossman HB (1994b) Loss of co-localization of alpha 6 beta 4 integrin and collagen VII in bladder cancer. Am J Pathol 144:787–795PubMedCentralPubMedGoogle Scholar
  106. Lipponen PK (1993) Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 53:365–370PubMedGoogle Scholar
  107. Lipponen PK (1995) Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J Pathol 175:203–210PubMedGoogle Scholar
  108. Lipponen PK (1996) Expression of cathepsin D in transitional cell bladder tumours. J Pathol 178:59–64PubMedGoogle Scholar
  109. Lipponen PK, Eskelinen MJ (1995) Reduced expression of Ecadherin is related to invasive disease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol 54:303–308Google Scholar
  110. Lipponen P, Aaltomaa S, Eskelinen M, Ala-Opas M, Kosma VM (1998) Expression of p21 (waf1/cip1) pro tein in transitional cell bladder tumours and its prognostic value.Eur Urol 34:237–243PubMedGoogle Scholar
  111. Liukkonen T, Rajala P, Raitanen M, Rintala E, Kaasinen E, Lipponen P (1999) Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (stage pTa/T1) bladder cancer: a prospective comparative study. Eur Urol 36:393–400PubMedGoogle Scholar
  112. Lloyd KO (1987) Philip Levine award lecture. Blood group antigens as markers for normal differentiation and malignant change in human tissues. Am J Clin Pathol87:129–139PubMedGoogle Scholar
  113. Logothetis CJ, Xu HJ, Ro JY et al. (1992) Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 84:1256–1261PubMedGoogle Scholar
  114. Lutzeyer W, Rübben H, Dahm H (1982) Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 127:250–252PubMedGoogle Scholar
  115. Maulard-Durdux C, Toubert ME, Hennequin C, Housset M (1997) Serum tissue polypeptide antigen in bladder cancer as a tumor marker: a prospective study. J Clin Oncol15:3446–3450PubMedGoogle Scholar
  116. Mellon JK, Lunec J, Wright C, Horne CH, Kelly P, Neal DE (1996) C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J UroI 155:321–326Google Scholar
  117. Messing EM (1990) Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 50:2530–2537PubMedGoogle Scholar
  118. Messing EM, Murphy-Brooks N (1994) Recovery of epidermal growth factor in voided urine of patients with bladder cancer. Urology 44:502–505PubMedGoogle Scholar
  119. Messing EM, Reznikoff CA (1987) Normal and malignant human urothelium: in vitro effects of epidermal growth factor. Cancer Res 47:2230–2235PubMedGoogle Scholar
  120. Messing EM, Reznikoff CA (1990) Binding and responsiveness to epidermal growth factor by in vitro transformants of normal urothelial cells. J Urol 143:272AGoogle Scholar
  121. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M (1999) Immunocyt: a new tool for detecting trans itional cell cancer of the urinary tract. J Urol 161:1486–1489PubMedGoogle Scholar
  122. Milella M, Jacobelli J, Cavallo F et al. (1999) Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder. Br J Cancer 79:770–779PubMedCentralPubMedGoogle Scholar
  123. Momose H, Kakinuma H, Shariff SY, Mitchell GB, Rademaker A, Oyasu R (1991) Tumor-promoting effect of urinary epidermal growth factor in rat urinary bladder carcinogenesis. Cancer Res 51:5487–5490PubMedGoogle Scholar
  124. Monia BP, Johnston JF, Geiger T, Müller M, Fabro D (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase.Nat Med 2:668–675PubMedGoogle Scholar
  125. Moolten F.L. (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46:5276–5281PubMedGoogle Scholar
  126. Moriyama M, Akiyama T, Yamamoto T, Kawamoto T (1991) Expression of c-erb-2 gene product in urinary bladder cancer. J Urol 145:423–427PubMedGoogle Scholar
  127. Mungan U, Kirkali G, Celebi I, Kirkali Z (1996) Significance of serum laminin PI values in patients with transitional cell carcinoma of the bladder. Urology 48:496–500PubMedGoogle Scholar
  128. Murphy WM, Rivera-Ramirez I, Medina CA, Wright NJ, Wajsman Z (1997) The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms. J Urol 158:2102–2106PubMedGoogle Scholar
  129. Naito S, Sakamoto N, Kotoh S, Goto K, Matsumoto T, Kumazawa J (1992) Correlation between the expression of Pglycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract. Eur Urol 22:158–162PubMedGoogle Scholar
  130. Nakagawa M, Emoto A, Nasu N et al. (1997) Clinical significance of multi-drug resistance associated protein and Pglycoprotein in patients with bladder cancer. J Urol 157:1260–1264PubMedGoogle Scholar
  131. Neal DE, Marsh C, Bennett MK et al. (1985) Epidermal growth factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1:366–368PubMedGoogle Scholar
  132. Nevins JR, Leone G, DeGregori J, Jakoi LJ (1997) Role of the Rb/E2F pathway in cell growth control. Cell Physiol 173:233–236Google Scholar
  133. Newman AJ Jr, Carlton CE Jr, Johnson S (1980) Cell surface A, B or O(H) blood group antigens as an indicator of malignant potential in stage Abladder carcinoma. J Urol 124:27–29PubMedGoogle Scholar
  134. Nitze M (1896) Die intravesikale Operation der Blasengeschwülste.Eduard Besold, BerlinGoogle Scholar
  135. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753–756PubMedGoogle Scholar
  136. Nunez C, Martinez-Pineiro L, Madrid FJ, Cisnero J, Viguer JW, Martinez-Pineiro JA (1999) Die Wertigkeit des BTA-Tests zur Erkennung des Blasenkarzinoms. Aktuelle Urol 30:112–117Google Scholar
  137. O’Flynn JD, Smith JM, Hanson JS (1975) Transurethral resection for the assessment and treatment of vesical neoplasms: a review of 840 consecutive cases. Eur Urol 1:38–40PubMedGoogle Scholar
  138. Ogura Y, Sato K, Kato T, Saito K, Enomoto K (1998) Immunohistochemical analysis of expression of angiogenic factors and tumor angiogenesis in superficial bladder cancer.Nippon Hinyokika Gakkai Zasshi 89:529–537PubMedGoogle Scholar
  139. Okamoto M, Hattori K, Fujimoto K, Tanaka Y, Gloosby CL, Oyasu R (1998) Antisense RNA-mediated reduction of p53 induces malignant phenotype in nontumorigenic rat urothelial Cells. Carcinogenesis 19:73–79PubMedGoogle Scholar
  140. Olumi AF, Tsai YC, Nichols PW et al. (1990) Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 50:7081–7083PubMedGoogle Scholar
  141. Orntoft TF, Wolf H (1998) Molecular alterations in bladder cancer. Urol Res 26:223–233PubMedGoogle Scholar
  142. Otto T, Birchmeier W, Schmidt U et al. (1994) Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res 54:3120–3123PubMedGoogle Scholar
  143. Ozawa M, Kemler R (1992) Molecular organization of the uvomorulin-catenin complex. J Cell Biol 116:989–996PubMedGoogle Scholar
  144. Ozdemir E, Kakehi Y, Okuno H, Yoshida O (1999) Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J Urol 161:1359–1363PubMedGoogle Scholar
  145. Ozer E, Mungan MU, Tuna B, Kazimoglu H, Yorukoglu K, Kirkali Z (1999) Prognostic significance of angiogenesis and immunoreactivity of cathepsin D and type IV collagen in high-grade stage Tl primary bladder cancer. Urology 54:50–55PubMedGoogle Scholar
  146. Pfister C, Moore L, Allard P et al. (1999) Predictive value of cell cycle markers p53, MDM2, p21, and Ki67 in superficial bladder tumor recurrence. Clin Cancer Res 5:4079–4084PubMedGoogle Scholar
  147. Phillips HA, Howard GC, Miller WR (2000) P53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer. Br J Cancer 82:136–141PubMedCentralPubMedGoogle Scholar
  148. Philp EA, Stephenson TJ, Reed MW (1996) Prognostic significance of angiogenesis in transitional cell carcinoma of the human urinary bladder. Br J Urol 77:352–357PubMedGoogle Scholar
  149. Plastiras D, Moutzouris G, Barbatis C, Presvelos V, Theodorou C, Petrakos M (1999) Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours? Eur J Surg Oncol 25:61–65PubMedGoogle Scholar
  150. Pode D, Golijanin D, Sherman Y, Lebensart P, Shapiro A (1998) Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors. J Urol 159:389–393PubMedGoogle Scholar
  151. Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I (1999) Noninvasive detection of bladder cancer with the BTA STAT test. J Urol 161:443–446PubMedGoogle Scholar
  152. Popov Z, Hoznek A, Colombel M et al. (1997) The prognostic value of p53 nuelear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 80:1472–1481PubMedGoogle Scholar
  153. Poulakis V, Witzsch U, Kollias A, Wolfram M, Becht E, Altmannsberßer H-M (1999) Vergleich des NMP22TM-und BTA-statTM-Tests mit der Urinzytologie und Zystoskopie in der Diagnose und Nachsorge des Blasenkarzinoms: Können die NMP22TM-und BTA-statTM-Tests die Zystoskopie ersetzen? Aktuelle Urol 30:466–475Google Scholar
  154. Presti JC Jr, Reuter VE, Galan T, Fair WR, Cordon-Cardo C (1991) Molecular genetic alterations in superficial and 10-cally advanced human bladder cancer. Cancer Res 51:5405–5409PubMedGoogle Scholar
  155. Protheroe AS, Banks RE, Mzimba M et al. (1999) Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer.Br J Cancer 80:273–278PubMedCentralPubMedGoogle Scholar
  156. Prout GR Jr, Barton BA, Griffin PP, Friedell GH, for the National Bladder Cancer Group (1992) Treated his tory of noninvasive grade 1 transitional cell carcinoma. J Urol 148:1413–1419PubMedGoogle Scholar
  157. Ramakumar S, Bhuiyan J, Besse JA et al. (1999) Comparison of screening methods in the detection of bladder cancer.J Urol 161:388–394PubMedGoogle Scholar
  158. Ravery V, Colombel M, Popov Z et al. (1995) Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer. Br J Cancer 71:196–200PubMedCentralPubMedGoogle Scholar
  159. Ravery V, Grignon D, Angulo J et al. (1997) Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res 25:9–17PubMedGoogle Scholar
  160. Reznikoff CA, Belair CD, Yeager TR et al. (1996) A molecular genetic model of human bladder cancer pathogenesis.Semin Oncol 23:571–584PubMedGoogle Scholar
  161. Rübben H, Terhorst B, Deutz FJ, Lagrange W, Giani G (1986) Unterschiedliche Färbeverfahren der exfoliativen Urinzytologie. Urologe A 25:302–305PubMedGoogle Scholar
  162. Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Soria F (1999) Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. J Urol 162:1951–1956PubMedGoogle Scholar
  163. Sandberg AA, Berger CS (1994) Review of chromosome studies in urologieal tumors. II. Cytogenetics and molecular genetics of bladder cancer. J Urol 151:545PubMedGoogle Scholar
  164. Sarkis AS, Dalbagni G, Cordon-Cardo C (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer lust 85:53Google Scholar
  165. Sarkis A, Bajorin DF, Reuter VE, Herr HW (1995) Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.J Clin Oncol 13:1384–1390PubMedGoogle Scholar
  166. Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS (1997) Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology 50:349–353PubMedGoogle Scholar
  167. Sato K, Moriyama M, Mori S, Saito M (1992) An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 70:2493–2498PubMedGoogle Scholar
  168. Sauter G, Haley J, Chew K, Kerschmann R (1994) Epidermal growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer 15:508–514Google Scholar
  169. Schmidt-Wolf IG, Finke S, Trojaneck B et al. (1999) Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.Br J Cancer 81:1009–1016PubMedCentralPubMedGoogle Scholar
  170. Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322PubMedGoogle Scholar
  171. Schöps W, Prior V, Golka K et al. (1997) Untersuchung zur klinischen Relevanz der Acetyliererphänotypisierung bei 196 Urotheltumorpatienten. Urologe A 36:64–67PubMedGoogle Scholar
  172. Sheinfeld J, Reuter VE, Melamed MR, Fair WR, Morse M (1990) Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J Urol 143:285–288PubMedGoogle Scholar
  173. Shiina H, Igawa M, Nagami H, Yagi H, Urakami S (1996) Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein and nuclear DNA content in transitional cell carcinoma of the bladder. Cancer 78:1762–1774PubMedGoogle Scholar
  174. Shimazui T, Schalken JA, Giroldi LA et al. (1996) Prognostic value of cadherin-associated molecules (alpha-, beta-and gamma catenins and pl20cas) in bladder tumors. Cancer Res 56:4154–4158PubMedGoogle Scholar
  175. Sidransky D, Eschenbach A von, Tsai YC et al. (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706–709PubMedGoogle Scholar
  176. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD (1992) Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359:67–70PubMedGoogle Scholar
  177. Soloway MS (1980) The management of superficial bladder cancer. Cancer 45:1865–1865Google Scholar
  178. Sorrentino BP, Brandt SJ, Bodine D et al. (1992) Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR I. Science 257:99–103PubMedGoogle Scholar
  179. Southgate J, Harnden P, Trejdosiewiez LK (1999) Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications. Histol Histopathol 14:657–664PubMedGoogle Scholar
  180. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M et al. (1994) Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54:784–788PubMedGoogle Scholar
  181. Sriplakich S, Jahnson S, Karlsson MG (1999) Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer? Br J Urol Int 83:498–503Google Scholar
  182. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J et al. (1998) Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 159:394–398PubMedGoogle Scholar
  183. Stein JP, Ginsberg DA, Grossfeld GD et al. (1998a) Effect of p21 WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer lust 90:1072–1079Google Scholar
  184. Stein JP, Grossfeld GD, Ginsberg DA et al. (1998b) Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 160:645–659PubMedGoogle Scholar
  185. Stieber P, Schmeller N, Schambeck C et al. (1996) Clinical relevance of CYFRA 21-1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancer. Anticancer Res 16:3793–3798PubMedGoogle Scholar
  186. Stöber K, Halsall I, Freeman A et al. (1999) Immunoassay for urothelial cancers that detects DNA replieation protein Mcm5 in urine. Lancet 354:1524–1525Google Scholar
  187. Sutton MA, Berkman SA, Chen SH et al. (1997) Adenovirusmediated suicide gene therapy for experimental bladder cancer. Urology 49:173–180PubMedGoogle Scholar
  188. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC (1999) Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 341:452–453PubMedGoogle Scholar
  189. Syrigos KN, Harrington K, Waxman J, Krausz T, Pignatelli M (1998) Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer. J Urol 160:1889–1893PubMedGoogle Scholar
  190. Takashi M, Schenck U, Kissel K, Leyh H, Treiber U (1999) Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients. Int Urol Nephrol 31:189–196PubMedGoogle Scholar
  191. Takeichi M (1991) Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251:1451–1455PubMedGoogle Scholar
  192. Taylor JA, Li Y, He M et al. (1996) P53 mutations in bladder tumors from arylamine-exposed workers. Cancer Res 56:294–298PubMedGoogle Scholar
  193. Thogersen VB, Jorgensen PE, Sorensen BS et al. (1999) Expression of transforming growth factor alpha and epidermal growth factor receptor in human bladder cancer. Scand J Clin Lab Invest 59:267–277PubMedGoogle Scholar
  194. Thompson IM, Peek M, Rodriguez FR (1987) The impact of cigarette smoking on stage, grade and number of recurrences of transitional cell carcinoma of the bladder. J Urol 137:401–403PubMedGoogle Scholar
  195. Tokunaga H, Lee DH, Kim IY, Wheeler TM, Lerner SP (1999) Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin Cancer Res 5:2520–2525PubMedGoogle Scholar
  196. Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, Jones PA (1990) Allelic losses of chromosomes 9, 11 and 17 in human bladder cancer. Cancer Res 50:44–47PubMedGoogle Scholar
  197. Tzai T-S, Lin CI, Shiau AL, Wu CL (1998) Antisense oligonucleotide specific for transforming growth factor-betal inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer. Anticancer Res 18:1585–1590PubMedGoogle Scholar
  198. UICC (1992) UICC TNM classification of malignant tumours.Springer, Berlin Heidelberg New YorkGoogle Scholar
  199. Underwood M, Bartlett J, Reeves J, Gardiner DS, Scott R, Cooke T (1995) C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 55:2422–2430PubMedGoogle Scholar
  200. Utz DC, Farrow GM (1984) Carcinoma in situ of the urinary tract. Urol Clin N Am 11:735–735Google Scholar
  201. Wajsman Z, Merrin CE, Chu TM, Moore RH, Murphy GP (1975) Evaluation of biological markers in bladder cancer. J Urol 114:879–893PubMedGoogle Scholar
  202. Waldman T, Lengauer C, Kinzler KW, Vogelstein B (1996) Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381:713–716PubMedGoogle Scholar
  203. Waldner M, Ubrig B, Roth S (1999) Screening und Nachsorge des Urothelkarzinoms-Welchen Stellenwert haben Tumormarker? Urologe B 39:321–324Google Scholar
  204. Weinstein RS, Alroy J, Farrow GM, Miller AW, Davidsohn I (1979) Blood group isoantigen deletion in carcinoma in situ of the urinary bladder. Cancer 43:661–668PubMedGoogle Scholar
  205. Wich H, Franke G, Grimm U, Siegmund W (1989) Zum Acetylierungsphänotyp bei Harnblasenkarzinompatienten. Z Urol Nephrol 82:597–600PubMedGoogle Scholar
  206. Williamson MP, Elder PA, Shaw ME, Devlin J, Knowles MA (1995) P16 (CDKN2) is a major deletion target al 9p21 in bladder cancer. Hum Mol Genet 4:1569–1577PubMedGoogle Scholar
  207. Xu H..J, Cairns P, Hu SX, Knowles MA, Benedict WF (1993) Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer 53:781–784PubMedGoogle Scholar
  208. Xu HJ, Zhou Y, Seigne J et al. (1996) Enhanced tumor suppressor gene therapy via replication-deficient protein. Adenovirus vectors expressing an N-terminal truncated retinoblastoma. Cancer Res 56:2245–2249PubMedGoogle Scholar
  209. Yamanaka K, Hara I, Nagai H et al. (1999) Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model. Cancer Immunol Immunother 48:297–302PubMedGoogle Scholar
  210. Yanez RJ, Porter AC (1999) Gene targeting is enhanced in human cells overexpressing hRAD51. Gene Ther 6:1282–1290PubMedGoogle Scholar
  211. Yao WJ, Chang CJ, Chan SH et al. (1995) Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma. Anticancer Res 15:2819–2823PubMedGoogle Scholar
  212. Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75:280–284PubMedCentralPubMedGoogle Scholar
  213. Zippe C, Pandrangi L, Agarwal A (1999) NMP22 is a sensitive,cost-effective test in patients at risk for bladder cancer.J Urol 161:62–65PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • Andreas Böhle
  • Sven Brandau
  • Christoph Durek
  • Peter Ardelt
  • Ingo Kausch

There are no affiliations available

Personalised recommendations